Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLH

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03920072
Recruitment Status : Recruiting
First Posted : April 18, 2019
Last Update Posted : November 27, 2019
Sponsor:
Information provided by (Responsible Party):
Kyowa Kirin Pharmaceutical Development Ltd

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 31, 2021
Estimated Study Completion Date : January 31, 2022